Pelin Kocyigit

Pelin Kocyigit

Auto-generated profile, based on publicly available information

Pelin Kocyigit

Department of Dermatology, Faculty of Medicine, Ankara University, Ankara, Turkey

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 November 2010 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay
PKP. Kocyigit
P. Kocyigit
AHAylin Okçu Heper
Aylin Okçu Heper
CEC. Erdem
C. Erdem

1 January 2002 in Ophthalmic Epidemiology
Verified
Journal Article
Closed access
AIA. Idil
A. Idil
AGA. Gürler
A. Gürler
ABA. Boyvat
A. Boyvat
DÇD. Çaliskan
D. Çaliskan
ÖÖÖ. Özdemir
Ö. Özdemir
EÇE. Çalikoglu
E. Çalikoglu
PURPOSE The aim of this study was to determine the prevalence of Behçet’s disease above the age of 10 years by means of a population-based study. METHODS The epidemiological investigation (cross-sectional study) was made between May 1997 and May 1998 at the Park Primary Health Care Center, which is one of the education and research divisions of the Department of Public Health, Faculty of Medicine, Ankara University. The research aimed to cover all 17,256 (49.2% male, 50.8% female) inhabitants over 10 years of age living in this area. The screening team first surveyed and selected patients with recurrent aphthous stomatitis. These patients were further examined, free of charge, in the Preventive Ophthalmology Unit of the Public Health Center, at Ibni Sina Hospital’s Behçet Center or in other clinics if necessary. In this study the International Study Group For Behçet’s disease Criteria were used. RESULTS As the final result of the screening, 11 female and 5 male patients with Behçet’s disease were found (f...

1 March 2018 in The Journal of Foot and Ankle Surgery
Verified
Journal Article
Closed access
PDF file
SVSeçil Vural
Seçil Vural
SBSeher Bostanci
Seher Bostanci
PKPelin Koçyigit
Pelin Koçyigit
DÇDeniz Çaliskan
Deniz Çaliskan
NBNilgun Baskal
Nilgun Baskal
NANursel Aydin
Nursel Aydin

20 February 2008 in Dermatology
Verified
Journal Article
Closed access
HSHatice Sanlı
Hatice Sanlı
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay
MAMutlu Arat
Mutlu Arat
PKPelin Koçyigit
Pelin Koçyigit
HAHamdi Akan
Hamdi Akan
OIOsman Ilhan
Osman Ilhan
Aim: To investigate the prevalence and clinical characteristics of vitiligo after allogeneic hematopoietic cell transplantation (AHCT). Methods: The development of vitiligo was analyzed among 421 patients who underwent AHCT in Ibni Sina Hospital (University of Ankara) between 1988 and 2004. Results: Among 421 patients, we describe 6 with generalized vitiligo occurring after AHCT for chronic myelogenous leukemia. Five of them had severe chronic graft-versus-host disease (GVHD). Vitiligo was accompanied by alopecia areata and acquired ichthyosis in 2 patients with GVHD. Conclusion: Melanocyte destruction caused by the autoimmune reactions triggered by chronic GVHD as well as a genetic predisposition might have played a role in the development of vitiligo in our patients. These data support the hypothesis that vitiligo is an autoimmune entity.

10 May 2016 in Journal of Dermatological Treatment
Verified
Journal Article
Closed access
AOAyse Oktem
Ayse Oktem
BABengu Nisa Nisa Akay
Bengu Nisa Nisa Akay
ABAyse Boyvat
Ayse Boyvat
NKNihal Kundakci
Nihal Kundakci
CECengizhan Erdem
Cengizhan Erdem
PKPelin Kocyigit
Pelin Kocyigit
Background: Epidermolysis bullosa acquisita (EBA) is a rare subepidermal bullous disease. Long-term remission in this disease is difficult using current treatments, unlike that in patients with other autoimmune bullous diseases. Objective: We retrospectively evaluated the effectiveness and side effects of rituximab–intravenous immunoglobulin (IVIg) combination treatment in five patients with EBA resistant to conventional treatment. Patients and methods: Rituximab (375 mg/m2) was administered for four consecutive weeks to four patients, and their treatment continued with IVIg at a dose of 2 g/kg/month. One patient received two cycles of rituximab for three consecutive weeks, IVIg in the fourth week, followed by monthly IVIg administrations as in the other patients. Results: The total number of IVIg therapy cycles ranged from 10 to 26 (mean 19.4). Mean skin involvement, mucosal involvement, and disease severity scores decreased after a mean follow-up of 22.6 months (range, 10–28 months). In an analysis performed during months 24–28, the number of CD19-positive B cells was found to be below the normal reference range in four patients. Limitations: This was a retrospective study with a limited number of patients. Conclusion: Rituximab–IVIg combination treatment seems to be effective and safe for treating patients with EBA resistant to conventional treatments.

1 June 2007 in Dermatologic Surgery
Verified
Journal Article
Closed access
PDF file
SBSeher Bostanci
Seher Bostanci
PKPelin Kocyigit
Pelin Kocyigit
EGErbak Gürgey
Erbak Gürgey
Chemical matricectomy is performed mainly by two agents: phenol and sodium hydroxide. Both agents have excellent cure rates, but there are no data about the comparison of postoperative healing periods. This study was designed to compare the postoperative morbidity rates of sodium hydroxide and phenol matricectomies. Forty-six patients with 154 ingrowing nail sides were treated with either sodium hydroxide or phenol matricectomy. In the postoperative period, the patients were evaluated for the duration and severity of pain, drainage, and peripheral tissue destruction; complete healing periods; and overall success rates. The incidence of pain was higher in the sodium hydroxide group on the first visit, on the second day, but all patients became pain-free after that. The incidence and duration of drainage and peripheral tissue destruction was significantly higher in the phenol group. The mean period for complete recovery was 10.8 days in the sodium hydroxide group, whereas it was 18.02 days in the phenol group. The overall success rates in the sodium hydroxide and phenol groups were found to be 95.1 and 95.8%, respectively. Both sodium hydroxide and phenol are effective agents giving high success rates, but sodium hydroxide causes less postoperative morbidity and provides faster recovery.